- Home
- IOR vs VERU Comparison
IOR vs VERU Comparison
Compare IOR & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOR
- VERU
- Stock Information
- Founded
- IOR 1984
- VERU 1971
- Country
- IOR United States
- VERU United States
- Employees
- IOR N/A
- VERU N/A
- Industry
- IOR Real Estate Investment Trusts
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- IOR Real Estate
- VERU Health Care
- Exchange
- IOR Nasdaq
- VERU Nasdaq
- Market Cap
- IOR 72.8M
- VERU 85.5M
- IPO Year
- IOR N/A
- VERU 1990
- Fundamental
- Price
- IOR $18.68
- VERU $3.59
- Analyst Decision
- IOR
- VERU Strong Buy
- Analyst Count
- IOR 0
- VERU 3
- Target Price
- IOR N/A
- VERU $33.33
- AVG Volume (30 Days)
- IOR 311.0
- VERU 209.1K
- Earning Date
- IOR 08-07-2025
- VERU 08-12-2025
- Dividend Yield
- IOR N/A
- VERU N/A
- EPS Growth
- IOR N/A
- VERU N/A
- EPS
- IOR 1.06
- VERU N/A
- Revenue
- IOR N/A
- VERU $16,886,419.00
- Revenue This Year
- IOR N/A
- VERU N/A
- Revenue Next Year
- IOR N/A
- VERU N/A
- P/E Ratio
- IOR $17.69
- VERU N/A
- Revenue Growth
- IOR N/A
- VERU 337.24
- 52 Week Low
- IOR $16.01
- VERU $2.64
- 52 Week High
- IOR $19.69
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- IOR 51.14
- VERU 31.53
- Support Level
- IOR $18.02
- VERU $2.64
- Resistance Level
- IOR $18.89
- VERU $4.00
- Average True Range (ATR)
- IOR 0.18
- VERU 0.40
- MACD
- IOR -0.01
- VERU -0.09
- Stochastic Oscillator
- IOR 79.38
- VERU 35.71
About IOR Income Opportunity Realty Investors Inc.
Income Opportunity Realty Investors Inc is a U.S.-based company that is an externally managed company that invests in mortgage notes receivables and real property. The business of the company is managed by Pillar Income Asset Management, Inc. The company's activities include locating, evaluating and recommending investment opportunities. Pillar also arranges its debt and equity financing with unaffiliated independent third party lenders and investors.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.